Biotechnology company NeuroMax invested by Maxwell Biotech fund set up with participation of RVC capital has completed qualification of patients for phase 3 of the clinical trial of BNV-222 innovation drug
Under the Cooperation Agreement, a technology brokerage development program in the Russian Federation and interregional network program for start-up schools with acceleration functions will be launched
On April 19, a seminar related to innovation management models and practices was held in the RVC office; it was a continuance of the project dated 2015 related to development of the instruments for experience exchange and promotion of the best corporate venture investment practices and "open innovation"
Hepatera LLC and it`s development partner MYR GmbH today announced the initiation of MYR 202, a Phase 2b open label, randomized clinical trial to evaluate efficacy and safety of Myrcludex B in combination with tenofovir in chronically HBV/HDV сo-infected patients
The portfolio company of the RBV Capital venture fund set up with participation of RVC capital, RetroSense Therapeutics started clinical tests of the medicine for partial recovery of the vision in patients with pigmented retinitis
On April 21-22, 2016 the Innovation Ecosystem: Universities and Scientific Centers Forum will be held in Moscow; it is organized by RVC in partnership with Lomonosovskiy Moscow State University, Innopractice Company and NUST MIS&S
The WiseSoil ecological project, an RVC SIF portfolio company, finalist of the GenerationS-2014 accelerator, became the winner of the Russian round of the Global Pioneers international program that is held in 32 cities of the world for the purpose of commercialization of the best technology solutions. WiseSoil "Green Technologies" significantly increase economic and energy efficiency of the organic wastes recycling and solve the problem of rich soil layer recovery